Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MorphoSys AG
MorphoSys AG
Activities:
Ingredients
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
MorphoSys and Immatics Biotechnologies sign immuno-oncology agreement
To develop antibody based therapies against multiple cancers
Research & Development
Merck Serono and MorphoSys agree immuno-oncology collaboration
MorphoSys\' Ylanthia antibody technology will be used to identify antibodies to fight tumours
Research & Development
MorphoSys and Heptares to develop antibody therapeutics targeting GPCRs
MorphoSys will apply Ylanthia library to develop products against StaRs from Heptares
Research & Development
MorphoSys expands 10-year antibody alliance with Novartis
Long-standing agreement will benefit from technologies not available in 2007
Ingredients
MorphoSys makes two management appointments
Charlotte Lohmann and Martin Clark join the German firm
Ingredients
MorphoSys unveils new antibody technology
Ylanthia will show higher success rates and shorter timelines in antibody drug development
Manufacturing
Boehringer signs manufacturing agreement with MorphoSys
Covers process development and manufacturing of clinical material for MOR208 antibody
Subscribe now